246 related articles for article (PubMed ID: 29319129)
41. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid.
Christian JA; Cook GJ; Harmer C
Br J Cancer; 2003 Jul; 89(2):258-61. PubMed ID: 12865913
[TBL] [Abstract][Full Text] [Related]
42. Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen.
Mohan V; Jones RC; Drake AJ; Daly PL; Shakir KM
Thyroid; 2005 Feb; 15(2):170-5. PubMed ID: 15753678
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue.
Robbins RJ; Hill RH; Wang W; Macapinlac HH; Larson SM
Thyroid; 2000 Feb; 10(2):177-83. PubMed ID: 10718556
[TBL] [Abstract][Full Text] [Related]
44. Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.
Agrawal K; Patro PSS; Preetam C
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940668
[TBL] [Abstract][Full Text] [Related]
45. Axillary lymph node metastasis in papillary thyroid carcinoma: report of a case and review of the literature.
Krishnamurthy A; Vaidhyanathan A
J Cancer Res Ther; 2011; 7(2):220-2. PubMed ID: 21768721
[TBL] [Abstract][Full Text] [Related]
46. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
[TBL] [Abstract][Full Text] [Related]
47. Does the presence of regional lymph node metastases have any impact on the complete remission rate in patients with distant metastases of papillary thyroid carcinoma (PTC), treated by radioiodine therapy?
Trybek T; Kowalska A
Endokrynol Pol; 2010; 61(5):443-5. PubMed ID: 21049455
[TBL] [Abstract][Full Text] [Related]
48. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
49. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
50. PANCREAS METASTASES FROM PAPILLARY THYROID CARCINOMA: A REVIEW OF THE LITERATURE.
Davidson M; Olsen RJ; Ewton AA; Robbins RJ
Endocr Pract; 2017 Dec; 23(12):1425-1429. PubMed ID: 29144798
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management.
Song H; Mosci C; Akatsu H; Basina M; Dosiou C; Iagaru A
Clin Nucl Med; 2018 Oct; 43(10):705-709. PubMed ID: 30153149
[TBL] [Abstract][Full Text] [Related]
52. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709
[TBL] [Abstract][Full Text] [Related]
53. [Value of (18)F-FDG dual head coincidence imaging in predicting the efficacy of radioiodine therapy for papillary thyroid carcinoma with cervical lymph node metastasis].
Sun YG; Feng HJ; Liu JH; Hu R; Ouyang W
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1571-4. PubMed ID: 21945769
[TBL] [Abstract][Full Text] [Related]
54. Is postablation whole-body
Liu B; Chen Y; Jiang L; He Y; Huang R; Kuang A
Clin Endocrinol (Oxf); 2017 Jan; 86(1):134-140. PubMed ID: 27434740
[TBL] [Abstract][Full Text] [Related]
55. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.
Garin E; Devillers A; Le Cloirec J; Bernard AM; Lescouarc'h J; Herry JY; Reubi JC; Bourguet P
Eur J Nucl Med; 1998 Jul; 25(7):687-94. PubMed ID: 9662589
[TBL] [Abstract][Full Text] [Related]
56. Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in graves' disease.
Gabriel M; Decristoforo C; Moncayo R
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1267. PubMed ID: 12418470
[No Abstract] [Full Text] [Related]
57. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
58. Quantitative uptake in 99m Tc-EDDA/HYNIC-TOC somatostatin receptor imaging - the effect of long-acting release somatostatin analogue therapy.
Gemmell AJ; Brown CM; Ray S; Small A
Nucl Med Commun; 2023 Nov; 44(11):944-952. PubMed ID: 37578312
[TBL] [Abstract][Full Text] [Related]
59. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
60. Preoperative scintigraphic visualization of lymph nodes and pulmonary metastases from papillary thyroid carcinoma.
Boughattas S; Hassine H; Arifa N; Chatti K; Degdegui M; Abdelkefi M; Essabbah H
Ann Nucl Med; 2004 Feb; 18(1):59-62. PubMed ID: 15072185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
